Takashi Niizeki
Overview
Explore the profile of Takashi Niizeki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheon J, Shimose S, Kim H, Niizeki T, Ryu M, Shirono T, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(2):52.
PMID: 39875560
Purpose: Atezolizumab-bevacizumab (AB) is the established first-line systemic therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, the optimal second-line treatment for patients unresponsive to AB remains undefined. Patients And...
2.
Suzuki H, Fukuda M, Shirono T, Kondo R, Tanaka T, Niizeki T, et al.
Intern Med
. 2024 Nov;
PMID: 39522997
Hepatic undifferentiated pleomorphic sarcoma (UPS) is a rare malignant mesenchymal tumor with unclear cancer-related genetic mutations. In a 60-year-old Japanese woman with a rapidly growing, inoperable hepatic UPS, a genetic...
3.
Moriyama E, Shimose S, Niizeki T, Iwamoto H, Tanaka M, Shirono T, et al.
Curr Oncol
. 2024 Oct;
31(10):5821-5831.
PMID: 39451736
This retrospective study aimed to evaluate the impact of atezolizumab plus bevacizumab-transcatheter arterial chemoembolization (TACE) sequential therapy in unresectable hepatocellular carcinoma (HCC), especially in patients with intermediate-stage HCC. A total...
4.
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, et al.
Oncology
. 2024 Oct;
:1-13.
PMID: 39396495
Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries...
5.
Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, et al.
Liver Cancer
. 2024 Sep;
13(5):522-536.
PMID: 39296620
Introduction: The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses of IMbrave-150 and...
6.
Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, Shirono T, et al.
Oncology
. 2024 Sep;
:1-12.
PMID: 39265538
Introduction: Atezolizumab (ATZ) and bevacizumab (BEV) combination therapy is widely used in patients with unresectable hepatocellular carcinoma (HCC). However, combination therapy is typically interrupted or discontinued owing to BEV-related adverse...
7.
Suzuki H, Shirono T, Niizeki T, Sugawara S, Kusano H, Kondo R, et al.
Intern Med
. 2024 Aug;
PMID: 39135246
Undifferentiated carcinoma of the liver is a rare and difficult-to-detect form of primary liver cancer. We herein report the first case of undifferentiated carcinoma of the liver in a 70-year-old...
8.
Suzuki H, Iwamoto H, Yamamoto K, Tsukaguchi M, Nakamura T, Masuda A, et al.
Gastro Hep Adv
. 2024 Aug;
1(4):555-562.
PMID: 39132059
Background And Aims: Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) progresses with a highly multicentric occurrence (MO) even after radical hepatectomy. Despite several efforts to clarify the pathogenesis of MO,...
9.
Suzuki H, Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, et al.
Gastro Hep Adv
. 2024 Aug;
3(4):506-509.
PMID: 39131724
No abstract available.
10.
Goto Y, Niizeki T, Sakai H, Akashi M, Fukutomi S, Hashimoto K, et al.
Anticancer Res
. 2024 Jul;
44(8):3629-3636.
PMID: 39060041
Background/aim: The outcome of hepatectomy for a hepatocellular carcinoma (HCC) exceeding 10 cm (i.e., huge HCC) remains unfavorable. The aim of the current study was to evaluate the optimal therapeutic...